As shown above, phagocytosis by TAMs can be enhanced eight-fold in breast cancer when CD47 is blocked (Willingham et al., 2012), which suggests that it could be a potential target for cancer treatment, and the present QSP platform may serve as a tool to make prospective efficacy predictions for this emerging strategy and its combination with other checkpoint inhibitors. This evidence concerns the gene CD47 and breast carcinoma.